HC Wainwright Has Pessimistic Outlook of UTHR Q4 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – HC Wainwright decreased their Q4 2026 EPS estimates for shares of United Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $6.44 for the quarter, down from their previous estimate of $6.94. The consensus estimate for United Therapeutics’ current full-year earnings is $26.32 per share. HC Wainwright also issued estimates for United Therapeutics’ FY2028 earnings at $37.53 EPS.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $6.41 EPS.

Several other equities research analysts also recently weighed in on UTHR. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Royal Bank Of Canada decreased their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $501.27 on Friday. The firm’s fifty day moving average price is $536.95 and its two-hundred day moving average price is $535.97. The stock has a market cap of $21.50 billion, a PE ratio of 17.93, a PEG ratio of 1.73 and a beta of 0.59. United Therapeutics has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,648,140.36. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 462,575 shares of company stock valued at $252,568,724 over the last quarter. 8.60% of the stock is owned by insiders.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. boosted its position in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC acquired a new position in United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC boosted its holdings in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its stake in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.